Company Number: 14334705

Analysis Date: 2025-07-20 13:28 UTC

Financial Health Assessment: KARM PHARMA LTD (as at 30 September 2024)

---

1. Financial Health Score: C

Explanation:
KARM PHARMA LTD exhibits some warning signs primarily related to liquidity and working capital management, as evidenced by ongoing net current liabilities. However, the company maintains positive net assets and shareholders’ funds, reflecting some capital buffer. Given the small scale (micro-entity) and early stage of the company (incorporated 2022), a moderate score reflects the need for cautious monitoring and improvement in short-term financial health.

---

2. Key Vital Signs

Metric	30 Sept 2024	Interpretation
Fixed Assets	£1,167	Small asset base typical for a micro company
Current Assets	£718	Cash and near-cash assets are very limited, indicating tight liquidity ("weak pulse")
Current Liabilities	£827	Short-term obligations slightly exceed current assets ("pressure on breathing")
Net Current Assets	-£109	Negative working capital ("symptom of distress")—company may struggle to cover short-term debts
Total Assets Less Current Liabilities	£1,058	Positive but declining compared to prior year, indicating some erosion of buffer
Net Assets / Shareholders Funds	£178	Equity capital is very low, indicating limited cushion against losses
Accruals and Deferred Income	£880	Significant deferred income liabilities, may represent advanced payments or unearned revenue

Additional Observations:

• Share capital is minimal at £100, with the majority of equity likely from retained earnings or other reserves.
• The company has maintained a small workforce of 2, consistent with micro entity status.
• No overdue filings, indicating compliance and no regulatory distress.
• The controlling director owns 75-100% shares and voting rights, indicating centralized control but also potential risk if over-reliant on a single individual.
• The company operates in specialized medical practice and dispensing chemist activities, sectors where cash flow timing and regulatory compliance are critical.

---

3. Diagnosis: Financial Condition Overview

KARM PHARMA LTD shows the symptoms of a young, small-scale enterprise with constrained liquidity. The negative net current assets point to a working capital squeeze, meaning the company may face challenges meeting short-term obligations without additional cash inflows or financing. This is a common issue in early-stage or small businesses but warrants attention to prevent liquidity crises.

The decline in net assets from £661 in 2023 to £178 in 2024 suggests the company may have absorbed losses or distributed funds without replenishing equity. While the company is not insolvent, the "financial pulse" is weak, with limited reserves to absorb shocks.

The presence of accruals and deferred income indicates the company may have income received in advance or expenses accrued but not yet paid, which requires careful management to ensure cash is available when obligations crystallize.

Overall, the company is viable but vulnerable, requiring improved cash flow management and possibly additional capital to strengthen its financial "immune system" against external shocks.

---

4. Recommendations

To improve financial wellness and move towards a healthier financial state, KARM PHARMA LTD should consider the following actions:

1. Enhance Liquidity Management:

   • Improve cash flow forecasting to anticipate and manage short-term funding needs.
   • Negotiate better payment terms with suppliers and customers to balance cash inflows and outflows.
   • Consider short-term financing options (overdrafts, invoice factoring) cautiously to alleviate working capital pressure.

2. Strengthen Equity Base:

   • Inject additional share capital or seek investment to increase net assets and provide a buffer for operational fluctuations.
   • Retain earnings where possible rather than dividend distributions to build reserves.

3. Review Cost Structure:

   • Examine operating expenses closely to identify and reduce non-essential costs without harming service quality.
   • Leverage efficiencies in staffing and procurement given the small team size.

4. Monitor Deferred Income and Accruals:

   • Ensure that deferred income is matched with related obligations and not masking cash flow shortages.
   • Confirm that accruals are accurate and payments are planned to avoid surprises.

5. Maintain Compliance and Governance:

   • Continue timely filing of accounts and confirmation statements to avoid penalties and maintain credibility.
   • Given the director’s controlling interest, consider establishing broader governance mechanisms as the company grows to mitigate concentration risk.

---